

Sachiko Seo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4458480/publications.pdf>

Version: 2024-02-01

67
papers

1,286
citations

394421

19
h-index

434195

31
g-index

74
all docs

74
docs citations

74
times ranked

2177
citing authors

#	ARTICLE	IF	CITATIONS
1	NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	89
2	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
3	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
4	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
5	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
6	Crk-Associated Substrate Lymphocyte Type Is Required for Lymphocyte Trafficking and Marginal Zone B Cell Maintenance. <i>Journal of Immunology</i> , 2005, 175, 3492-3501.	0.8	58
7	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
8	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
9	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
10	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
11	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
12	Cas Adaptor Proteins Organize the Retinal Ganglion Cell Layer Downstream of Integrin Signaling. <i>Neuron</i> , 2014, 81, 779-786.	8.1	34
13	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
14	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	1.4	34
15	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
16	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
17	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
18	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Structure and Function of Cas-L and Integrin-Mediated Signaling. <i>Critical Reviews in Immunology</i> , 2006, 26, 391-406.	0.5	21
20	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	2.5	19
21	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
22	Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1784-1795.	2.4	17
23	Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, e620-e628.	5.8	16
24	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
25	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
26	Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210 ^{Bcr/Abl} . <i>Cancer Science</i> , 2011, 102, 2109-2117.	3.9	14
27	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
28	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
29	Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. <i>Brain Communications</i> , 2020, 2, fcz048.	3.3	14
30	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
31	NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1533-1545.	5.6	14
32	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	5.2	13
33	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
34	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
35	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
36	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12

#	ARTICLE	IF	CITATIONS
37	Identification of Nedd9 as a TGF- β 2-Smad2/3 Target Gene Involved in RANKL-Induced Osteoclastogenesis by Comprehensive Analysis. PLoS ONE, 2016, 11, e0157992.	2.5	11
38	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Advances, 2020, 4, 706-716.	5.2	11
39	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
40	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	1.2	11
41	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1744-1755.	2.0	10
42	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica, 2023, 108, 150-160.	3.5	10
43	Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia. Blood, 2020, 136, 31-32.	1.4	9
44	Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. Biology of Blood and Marrow Transplantation, 2020, 26, 1363-1370.	2.0	8
45	Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies. Cancer Science, 2021, 112, 331-338.	3.9	8
46	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820.	1.3	7
47	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
48	Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood, 2021, 138, 1628-1636.	1.4	7
49	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. Blood Advances, 2019, 3, 1750-1760.	5.2	6
50	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
51	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
52	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4
53	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	1.2	4
54	Incidentally detected t(9;22)(q34;q11) BCR-ABL ⁺ positive clone developing into chronic phase chronic myeloid leukaemia after four years of dormancy. British Journal of Haematology, 2016, 174, 815-817.	2.5	3

#	ARTICLE	IF	CITATIONS
55	Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 400-410.	2.4	3
56	Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. Bone Marrow Transplantation, 2021, 56, 2410-2422.	2.4	3
57	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
58	Emergence of t(3;21)(q26.2;q22) during eltrombopag treatment in a patient with relapsed aplastic anemia who received chemotherapy for angioimmunoblastic T-cell lymphoma. Leukemia Research Reports, 2022, 17, 100305.	0.4	1
59	PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 239-242.	1.3	0
60	Cas-L/Hef1 Is Required for Marginal Zone B Cell Maintenance and Lymphocyte Trafficking.. Blood, 2005, 106, 3920-3920.	1.4	0
61	Cas-L Suppresses Progression of Leukemia Induced by p210Bcr/Abl.. Blood, 2006, 108, 4816-4816.	1.4	0
62	Plasma Brain Natriuretic Peptide Is Associated with Hepatic Veno-Occlusive Disease and Early Mortality After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 3348-3348.	1.4	0
63	Clinical Characteristics and GVL Effect of Chronic Graft-Versus-Host disease Following Reduced-Intensity Umbilical Cord Blood Transplantation (RICBT).. Blood, 2009, 114, 1162-1162.	1.4	0
64	Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 3318-3318.	1.4	0
65	Impact of Low-Dose TBI on Outcome of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from HLA Identical Sibling for Acute Myeloid Leukemia. Blood, 2014, 124, 3893-3893.	1.4	0
66	Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age. Blood, 2019, 134, 46-46.	1.4	0
67	Esophageal intramucosal hematoma after peripheral blood stem cell transplantation: case report and review of literature. International Journal of Clinical and Experimental Pathology, 2014, 7, 2690-4.	0.5	0